Literature DB >> 20796001

Reducing fracture risk with calcium and vitamin D.

Paul Lips1, Roger Bouillon, Natasja M van Schoor, Dirk Vanderschueren, Sabine Verschueren, Natalia Kuchuk, Koen Milisen, Steven Boonen.   

Abstract

Studies of vitamin D and calcium for fracture prevention have produced inconsistent results, as a result of different vitamin D status and calcium intake at baseline, different doses and poor to adequate compliance. This study tries to define the types of patients, both at risk of osteoporosis and with established disease, who may benefit from calcium and vitamin D supplementation. The importance of adequate compliance in these individuals is also discussed. Calcium and vitamin D therapy has been recommended for older persons, either frail and institutionalized or independent, with key risk factors including decreased bone mineral density (BMD), osteoporotic fractures, increased bone remodelling as a result of secondary hyperparathyroidism and increased propensity to falls. In addition, treatment of osteoporosis with a bisphosphonate was less effective in patients with vitamin D deficiency. Calcium and vitamin D supplementation is a key component of prevention and treatment of osteoporosis unless calcium intake and vitamin D status are optimal. For primary disease prevention, supplementation should be targeted to those with dietary insufficiencies. Several serum 25-hydroxyvitamin D (25(OH)D) cut-offs have been proposed to define vitamin D insufficiency (as opposed to adequate vitamin D status), ranging from 30 to 100 nmol/l. Based on the relationship between serum 25(OH)D, BMD, bone turnover, lower extremity function and falls, we suggest that 50 nmol/l is the appropriate serum 25(OH)D threshold to define vitamin D insufficiency. Supplementation should therefore generally aim to increase 25(OH)D levels within the 50-75 nmol/l range. This level can be achieved with a dose of 800 IU/day vitamin D, the dose that was used in successful fracture prevention studies to date; a randomized clinical trial assessing whether higher vitamin D doses achieve a greater reduction of fracture incidence would be of considerable interest. As calcium balance is not only affected by vitamin D status but also by calcium intake, recommendations for adequate calcium intake should also be met. The findings of community-based clinical trials with vitamin D and calcium supplementation in which compliance was moderate or less have often been negative, whereas studies in institutionalized patients in whom medication administration was supervised ensuring adequate compliance demonstrated significant benefits.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20796001     DOI: 10.1111/j.1365-2265.2009.03701.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  55 in total

1.  Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden.

Authors:  H Johansson; A Odén; J Kanis; E McCloskey; M Lorentzon; Ö Ljunggren; M K Karlsson; P M Thorsby; Å Tivesten; E Barrett-Connor; C Ohlsson; D Mellström
Journal:  Osteoporos Int       Date:  2011-10-19       Impact factor: 4.507

Review 2.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

3.  Additive association of vitamin D insufficiency and sarcopenia with low femoral bone mineral density in noninstitutionalized elderly population: the Korea National Health and Nutrition Examination Surveys 2009-2010.

Authors:  S-G Lee; Y-h Lee; K J Kim; W Lee; O H Kwon; J-H Kim
Journal:  Osteoporos Int       Date:  2013-05-08       Impact factor: 4.507

4.  Hip fracture prevention with a multifactorial educational program in elderly community-dwelling Finnish women.

Authors:  T Pekkarinen; E Löyttyniemi; M Välimäki
Journal:  Osteoporos Int       Date:  2013-05-08       Impact factor: 4.507

5.  Antiepileptic medications increase osteoporosis risk in male fabry patients: bone mineral density in an Australian cohort.

Authors:  Andrew Talbot; Joanna R Ghali; Kathy Nicholls
Journal:  JIMD Rep       Date:  2014-07-26

6.  Secular trends in the use of vitamins, minerals and fish-oil products in two cohorts of community-dwelling older people in Helsinki--population-based surveys in 1999 and 2009.

Authors:  N Savikko; K H Pitkälä; J V Laurila; M H Suominen; R S Tilvis; H Kautiainen; T E Strandberg
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

Review 7.  Vitamin D and bone health: Epidemiologic studies.

Authors:  Peter R Ebeling
Journal:  Bonekey Rep       Date:  2014-03-05

8.  Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF outcome.

Authors:  Georgios M Anifandis; Konstantinos Dafopoulos; Christina I Messini; Nektarios Chalvatzas; Nikolaos Liakos; Spyros Pournaras; Ioannis E Messinis
Journal:  Reprod Biol Endocrinol       Date:  2010-07-28       Impact factor: 5.211

9.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club.

Authors:  J-J Body; P Bergmann; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

10.  Clinical utility of vitamin d testing: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.